Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Receivables (2018 - 2025)

Fate Therapeutics' Change in Receivables history spans 7 years, with the latest figure at $233000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 139.63% year-over-year to $233000.0; the TTM value through Dec 2025 reached -$2.6 million, down 335.76%, while the annual FY2025 figure was -$2.6 million, 335.76% down from the prior year.
  • Change in Receivables reached $233000.0 in Q4 2025 per FATE's latest filing, up from -$713000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $28.3 million in Q4 2022 to a low of -$25.0 million in Q1 2023.
  • Average Change in Receivables over 5 years is -$260050.0, with a median of -$650500.0 recorded in 2024.
  • Peak YoY movement for Change in Receivables: skyrocketed 1970.11% in 2022, then plummeted 1373.2% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $1.4 million in 2021, then surged by 1970.11% to $28.3 million in 2022, then tumbled by 98.98% to $288000.0 in 2023, then crashed by 304.17% to -$588000.0 in 2024, then surged by 139.63% to $233000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Change in Receivables are $233000.0 (Q4 2025), -$713000.0 (Q3 2025), and -$1.0 million (Q2 2025).